Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm to Offer Millions of Advanta COVID-19 Tests at Low Cost to U.S. Colleges and Universities
Fluidigm COVID-19 Campus Safeguard Program Improves Availability of Non i nvasive, Saliva-Based SARS-CoV-2 Test s   for Higher Education   Institutions High-Throughput , Integrated Testing Platform and Reliable Supply Chain SOUTH SAN FRANCISCO, Calif. , Oct.
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2020 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2020 financial results on Thursday,
View HTML
Toggle Summary Fluidigm Joins Global Consortium of Cancer Prevention Experts
CANCERPREV Cross-Disciplinary Program Expands Knowledge of Cancer Development to Deliver New Insights into Prevention Strategies Principal Focus on Advancing Understanding of Breast and Skin Cancer Risks SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary ImmunoGenomics and Vero Diagnostics Providing COVID-19 Testing with Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay on Biomark HD Platform
Regional CLIA-Certified Labs among Growing Number of Customers Expanding SARS-CoV-2 Testing with Fluidigm Technology SOUTH SAN FRANCISCO, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm Announces Agenda for 9th Annual Mass Cytometry Summit
Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry Leading Academic and Pharma Researchers Detail Latest CyTOF Based Discoveries in Infectious Disease, Immunology and the Tumor Microenvironment SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Fluidigm Achieves Initial Milestone under NIH Rapid Acceleration of Diagnostics Agreement
SOUTH SAN FRANCISCO, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced progress on the Company’s Rapid Acceleration of Diagnostics (RADx)
View HTML
Toggle Summary Fluidigm to Participate at the 2020 Cantor Virtual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in investor meetings and
View HTML
Toggle Summary Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR  Assay for COVID-19
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System   Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Calif. , Aug.
View HTML
Toggle Summary Fluidigm Announces Second Quarter 2020 Financial Results
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay Fluidigm Selected for $37 Million Project under
View HTML
Toggle Summary Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis
License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging Systems SOUTH SAN FRANCISCO, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to
View HTML